Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

  • Meridian Bioscience Inc VIVO reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of $99.54 million.
  • Revenues from the life science division grew 32% Y/Y to $70.1 million. Diagnostic segment sales rose 29% to $41.1 million.
  • Within diagnostics, molecular assay revenues were flat at $4.4 million. Non-molecular assay revenues climbed 33% to $36.7 million.
  • In the life sciences division, revenues from molecular reagents were $40.3 million, up 7%, and revenues from immunological reagents were $29.8 million, up 91%. 
  • The company said that the product mix shifted away from molecular reagents to immunological reagents due to higher demand for COVID-19 rapid antigen tests.
  • Adjusted EPS was $0.66, ahead of the consensus of $0.47 and $0.56 a year ago.
  • The company finished the quarter with cash and cash equivalents of $76.5 million.
  • Guidance: Meridian raised FY22 sales guidance to $330 million - $345 million (consensus $337.62 million), better than the previous guidance of $315 million - $330 million.
  • The guidance includes life science revenues of $185 million - $195 million, vs. the prior range of $170 million - $180 million.
  • Diagnostics revenue guidance remains unchanged at between $145 million - $150 million. 
  • The company expects an adjusted EPS of $1.30 - $1.40 (consensus $1.37) versus the earlier outlook of $1.10 - $1.30.
  • This guidance anticipates that life sciences revenues will drop in the second half of the year as demand decreases for reagents used in COVID-19 tests.
  • Price Action: VIVO shares are down 2.99% at $25.82 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!